GBT is working to discover, develop and deliver life-changing treatments for people living with grievous blood-based disorders, starting with sickle cell disease
Our goal is to transform the treatment of sickle cell disease (SCD), an overlooked rare condition, and help address the urgent needs of the community. Our mission is driven by the historical lack of understanding and attention given to SCD. Although the fundamental cause of SCD has been understood for decades, therapeutic innovation and access to care has significantly lagged.
GBT’s medicine is the first treatment approved by the FDA to target an underlying cause of SCD. We are developing additional investigational treatments that have the potential to better the lives of patients.
Our history: we’re proud of all we have accomplished alongside the SCD community in our first 10 years and remain committed to our goal of changing the treatment paradigm in SCD.
